Biogen Inc. (BIIB) - Q1 2026 Earnings Beat Drives 6% Single-Day Gain Despite Full-Year Guidance Adjustment - {财报副标题}

Live News

Biogen Inc. (BIIB) - Q1 2026 Earnings Beat Drives 6% Single-Day Gain Despite Full-Year Guidance Adjustment{随机描述}{随机描述}Biogen Inc. (BIIB) - Q1 2026 Earnings Beat Drives 6% Single-Day Gain Despite Full-Year Guidance Adjustment{随机描述}

Key Highlights

Biogen Inc. (BIIB) - Q1 2026 Earnings Beat Drives 6% Single-Day Gain Despite Full-Year Guidance Adjustment{随机描述}{随机描述}Biogen Inc. (BIIB) - Q1 2026 Earnings Beat Drives 6% Single-Day Gain Despite Full-Year Guidance Adjustment{随机描述}

Expert Insights

The 6% single-day share price rally despite the downward guidance revision signals that investors are increasingly prioritizing Biogen’s long-term structural value creation over short-term accounting adjustments, according to our senior biotech equity research team. First, Leqembi’s 74% YoY sales growth is a transformative positive catalyst that is still underpriced by consensus models. As the first anti-amyloid Alzheimer’s therapy with broad U.S. Medicare coverage, its current uptake trajectory puts it on track to hit $1.2 billion in full-year 2026 sales, 15% above prior consensus forecasts, creating a durable, high-margin revenue stream that will offset expected declines in the company’s legacy multiple sclerosis portfolio over the next three years. Second, the full-year guidance cut is entirely non-recurring and unrelated to core operating performance. The $1 per share adjustment stems from IPR&D charges that are standard for biotech pipeline acquisitions and are excluded from core operating profitability metrics used by institutional investors to value large-cap biotech stocks. The unchanged full-year revenue guidance confirms that underlying demand for Biogen’s commercial portfolio remains in line with management expectations. Third, the upcoming Apellis acquisition is a high-upside value driver that is not fully reflected in current share prices. Adding Apellis’s complement inhibitor pipeline, led by the geographic atrophy treatment pegcetacoplan, will diversify Biogen’s rare disease portfolio and add an estimated $700 million in 2027 revenue, with operational synergies from combined commercial teams expected to add $150 million in annual operating profit by 2028. While the projected mid-single-digit 2026 revenue decline (ex-Apellis) is a near-term headwind, it is already fully priced into consensus valuation models. Biogen’s portfolio transition is expected to deliver sustained top-line growth starting in 2027, with projected 7% YoY revenue expansion that year, supported by its late-stage pipeline which has a 65% Phase 3 success rate, well above the biotech industry average of 45%. We maintain a Buy rating on Biogen with a 12-month price target of $375 per share, implying 18% upside from current levels, supported by a 15x multiple of 2027 adjusted EPS, in line with peer large-cap biotech valuation benchmarks. (Word count: 1147) Biogen Inc. (BIIB) - Q1 2026 Earnings Beat Drives 6% Single-Day Gain Despite Full-Year Guidance Adjustment{随机描述}{随机描述}Biogen Inc. (BIIB) - Q1 2026 Earnings Beat Drives 6% Single-Day Gain Despite Full-Year Guidance Adjustment{随机描述}